OneCell Diagnostics Inc.

Happy New Year 2025 from OneCell Diagnostics! ✨🎉 As we step into 2025, we express our heartfelt gratitude to all our partners, clients, and team members for being an integral part of our journey. At OneCell Diagnostics, we are committed to accelerating precision care and pushing the boundaries of innovation in cancer diagnostics. Wishing you a Happy, Healthy, and Successful New Year! 🌟 #OneCellDiagnostics #PrecisionOncology #Innovation2025 #NewYearWishes Mohan Uttarwar Dr. Gowhar S. Jayant Khandare Aravindan Vasudevan Surinnder Dang Srikanth Katturwar DHRUV BHATIA Atul Bharde

🎄 Merry Christmas from OneCell Diagnostics! 🎄 We extend warm wishes to our community, partners, and supporters. May your Christmas be filled with joy, health, and moments of togetherness. Here's to a year ahead full of breakthroughs and new possibilities! #onecelldx #christmas #merrychristmas #onecelldiagnostics Mohan Uttarwar Dr. Gowhar S. Jayant Khandare Aravindan Vasudevan Surinnder Dang Srikanth Katturwar DHRUV BHATIA

We attended the 8th Annual Year-End Review in Lung Cancer, held from December 20–22, 2024, in Mumbai. This prestigious event brought together India’s leading oncologists and researchers, who explored the latest innovations in precision oncology diagnostics at our booth. Our experts contributed valuable insights: Dr. Gowhar S., Chief Medical Geneticist: Presented on "Understanding Liquid Biopsy Application in Real-World Lung Cancer Patients." Dr. Jayant Khandare, Chief Scientific Officer: Delivered a talk on "Acceptance of CTC Reports in Lung Cancer Clinics" and participated in a panel discussion titled "cfDNA, CTC, Actionable Biomarkers in Liquid Biopsy." Both sessions underscored the transformative potential of data-driven precision oncology, sparking valuable discussions aimed at advancing patient care. We sincerely thank everyone who visited our booth and joined us in shaping the future of oncology through innovation and precision. #LungCancerReview #PrecisionOncology #OneCellDiagnostics #CancerResearch #OncologyInnovation #Genomics #AIinHealthcare #OncologyLeadership #LungCancer #LungCancerReview #PrecisionOncology #OneCellDiagnostics #CancerResearch #OncologyInnovation #Genomics #AIinHealthcare #OncologyLeadership #LungCancer Mohan Uttarwar Aravindan Vasudevan Surinnder Dang DHRUV BHATIA Srikanth Katturwar Atul Bharde Pankaj Keer Suniti Sharma

We participated in the Aster Cancer Conclave 2024, held in Bangalore from December 13-15. This prestigious event brought together top oncologists and researchers from across India, who visited our stall to explore the latest advancements in precision oncology diagnostics. Our Chief Medical Geneticist, Dr. Gowhar S. Shafi, participated in multiple panel discussions. His insights emphasized the critical role of data-driven precision in cancer treatment, sparking engaging discussions with experts dedicated to advancing patient care. A heartfelt thank you to everyone who visited our booth and connected with us. Together, we're shaping the future of oncology with precision and innovation. #AsterCancerConclave #PrecisionOncology #OneCellDiagnostics #CancerResearch #OncologyInnovation #Genomics #AIinHealthcare #OncologyLeadership #asterhospitals Mohan Uttarwar Aravindan Vasudevan Jayant Khandare Atul Bharde Surinnder Dang Srikanth Katturwar syed owais bukhari Pushpa Singh Imtiaz Naik DHRUV BHATIA

We participated in the International Society of Liquid Biopsy (ISLB) – Annual Congress 2024, held from November 23-25 in Denver, Colorado, USA. We launched and showcased: OneCell Solo – our innovative and breakthrough CTC (circulating tumor cell) capture and cell release automation instrument. We presented: OncoIndx Ikon, a multi-omics assay designed to capture true live single circulating tumor cells (sCTC) with ctDNA clinical studies outcomes and comparisons to ctDNA. On Monday, November 25th, we hosted a session titled: "Chartering the Future of Liquid Biopsy: ctDNA + CTC Multi-omics (DNA+RNA+Proteins)" This session was moderated by esteemed — Dr. David Gandara, Dr. Christian Rolfo, MD, PhD, MBA,Dr.hc. The panelists were Dr. Ken Bloom, Mr. Mohan Uttarwar, Dr. Jayant Khandare, and Dr. Gowhar S. — the session explored CTC 3.0 technology with its novel genomics insights at true single cell- beyond what is known in the field. In addition, we presented 04 posters titled - 1) Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients 2) Comprehensive Analysis of ctDNA and CTCs Reveals Resistance Signatures and Correlations with PET Scan Outcomes in Cancer Patients 3) Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients 4) Downstream effector mutations indicate potential tyrosine kinase inhibitor resistance in EGFR mutated lung cancer patients. The engaging discussions, interactive sessions, and collaborations with global oncology leaders further inspired us in our mission to revolutionize cancer care. We extend our heartfelt gratitude to all attendees who visited our booth and joined the discussions. Together, we are charting the future of cancer discovery. #ISLB2024 #PrecisionOncology #CancerResearch #OneCellDiagnostics #LiquidBiopsy #CTC #ctDNA #SingleCellAnalysis #InnovationInCancerCare #OneCellDx Aravindan Vasudevan Surinnder Dang DHRUV BHATIA Atul Bharde Ajay Pandita Padma Sundar Srikanth Katturwar

OneCell Diagnostics Inc., a genomics-based precision oncology company based in Cupertino, CA, and Mumbai, India, raised $16M in Series A Funding. Celesta Capital led the round, which also included Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will join the OneCell board of directors. https://lnkd.in/geXnqcqn

OneCell Diagnostics Inc., a genomics-based precision oncology company, on Thursday announced that it has raised $16 million in an oversubscribed Series A funding round led by Celesta Capital, with participation from Tenacity Ventures, Cedars-Sinai, Eragon, and Singularity Ventures.

#Update Celesta Capital led the Series A round, with participation from Tenacity Ventures, Cedars-Sinai, Eragon Ventures, and Singularity Ventures. OneCell Diagnostics Inc., a Pune-based cancer diagnostics startup, has raised USD 16 million in Series A funding led by Celesta Capital. This funding will fuel the US expansion of OncoIndx Alfa, a next-generation liquid biopsy test. This innovative test leverages advanced technologies to detect circulating tumor cells, enabling precise cancer diagnosis and monitoring. OneCell Diagnostics Inc.'s B2B2C model delivers these tests through oncologists and hospitals. With a strong team, strategic partnerships, and a focus on personalized cancer care, OneCell Diagnostics Inc. aims to revolutionize global cancer diagnostics. Read the story: https://ow.ly/FszE50Ucvsa Mohan Uttarwar, Co-founder and CEO, OneCell Diagnostics Inc. #StartupFunding #CancerDiagnostics #SeriesAFunding #Biotech #LiquidBiopsy #HealthTech #Oncology #PersonalizedMedicine #InnovationInHealthcare #Diagnostics

We at Celesta Capital are excited about working with the OneCell Diagnostics Inc. team as they build a company based on their unique liquid biopsy technology for cancer diagnostics. https://lnkd.in/gEPe7QJ2

We’re excited to share that Celesta Capital is leading the Series A round for OneCell Diagnostics Inc.. A company at the frontiers of precision oncology and a great example of the power of the U.S.-India corridor. Congratulations Mohan Uttarwar, Jayant Khandare, Gowhar S., Aravindan Vasudevan, Surinnder Dang and the OneCell team.